Two-drugvs. three-drug combinations for HIV-1: Do we have enough data to make the switch?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Two-drugvs. three-drug combinations for HIV-1: Do we have enough data to make the switch?

Published:2019-03-01 Issue: Volume:20 Page:2-12
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Moreno S¹,Perno CF²,Mallon PW³,Behrens G⁴,Corbeau P⁵⁶,Routy J-P⁷,Darcis G⁸

Affiliation:

1. Department of Infectious Diseases; University Hospital Ramón y Cajal; Alcalá University; IRYCIS; Madrid Spain

2. Department of Laboratory Medicine; ASST Niguarda Hospital; University of Milan; Milan Italy

3. HIV Molecular Research Group; School of Medicine; University College Dublin; Dublin Ireland

4. Department for Rheumatology and Clinical Immunology; Hannover Medical School; Hannover Germany

5. Institute for Human Genetics; CNRS-Montpellier University UMR9002; Montpellier France

6. Immunology Department; University Hospital; Nîmes France

7. Division of Hematology and Chronic Viral Infection Service; McGill University Health Centre; Montréal QC Canada

8. Department of Infectious Diseases; Liege University Hospital; University of Liege; Liège Belgium

Funder

Gilead Sciences Europe Ltd

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hiv.12716/fullpdf

Reference79 articles.

1. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis;Odone;PLoS One,2014

2. Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy;Sezgin;HIV Med,2018

3. HIV infection, immune suppression and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users;Salter;Clin Infect Dis,2011

4. The role of tenofovir alafenamide in future HIV management;Antela;HIV Medicine,2016

5. The effect of treatment simplification on HIV reservoirs;Darcis;Lancet,2017

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain;Viruses;2024-02-06

2. Dynamical analysis of nonlinear combined drug therapy model for HIV infection: Bayesian regularization technique intelligent networks;Biomedical Signal Processing and Control;2024-02

3. Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19;Reviews in Medical Virology;2023-12-21

4. Anti-CD4 antibody and dendrimeric peptide based targeted nano-liposomal dual drug formulation for the treatment of HIV infection;Life Sciences;2023-12

5. HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors;Biomedicine & Pharmacotherapy;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3